Accepted for Publication: November 17, 2022.
Published Online: January 25, 2023. doi:10.1001/jamadermatol.2022.6045
Corresponding Author: Derek K. Chu, MD, PhD, Department of Medicine, McMaster University. Room 3H30 McMaster University Medical Centre, 1280 Main St West, Hamilton, Ontario, Canada (chudk@mcmaster.ca).
Author Contributions: Drs Maleki-Yazdi and Chu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Maleki-Yazdi, Heen, Zhao, Guyatt, Makhdami, Winders, Wheeler, Spergel, Silverberg, Ong, LeBovidge, Frazier, Capozza, De Benedetto, Schneider, Chu.
Acquisition, analysis, or interpretation of data: Maleki-Yazdi, Heen, Zhao, Suzumura, Makhdami, Chen, Wang, Silverberg, Ong, O'Brien, Martin, Lio, Lind, Kim, Huynh, Greenhawt, Ellison, Boguniewicz, Smith Begolka, Asiniwasis, Schneider, Chu.
Drafting of the manuscript: Maleki-Yazdi, Heen, Zhao, Makhdami, Kim, Huynh, Frazier, Ellison, Chu.
Critical revision of the manuscript for important intellectual content: Maleki-Yazdi, Heen, Zhao, Guyatt, Suzumura, Makhdami, Chen, Winders, Wheeler, Wang, Spergel, Silverberg, Ong, O'Brien, Martin, Lio, Lind, LeBovidge, Greenhawt, Capozza, De Benedetto, Boguniewicz, Smith Begolka, Asiniwasis, Schneider, Chu.
Statistical analysis: Maleki-Yazdi, Zhao, Makhdami, Winders, Wheeler, Chu.
Obtained funding: Chu.
Administrative, technical, or material support: Maleki-Yazdi, Zhao, Makhdami, Chen, O'Brien, Schneider, Chu.
Supervision: Maleki-Yazdi, Heen, Guyatt, Wang, Spergel, Ong, Greenhawt, Frazier, De Benedetto, Chu.
Conflict of Interest Disclosures: Dr Wang reported grants from DBV Technologies, Aimmune, and Regeneron; and personal fees from ALK Abello, Genentech, and Jubilant HollisterStier outside the submitted work. Mrs Winders reported that her institution has received funding for unbranded disease awareness and education from the following: AbbVie, ALK, Amgen, AstraZeneca, Incyte, Lilly, GSK, Novartis, Pfizer, Sanofi/Regeneron, and TEVA. Dr Spergel reported grants from Abbott, Food Allergy Research and Education, Novartis, Regeneron, Sanofi, and Takeda; and royalties from UpToDate outside the submitted work. Dr Spergel also reported receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Medscape and Rockpointe; and being on the safety monitoring board or advisory board of the National Institute of Allergy and Infectious Disease and Syneos. Dr Silverberg reported personal fees from AbbVie, AObiome, Arcutis, Alamar, Amgen, Arena, Arcutis, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi Genzyme, Shaperon, Union; and grants from Incyte and Pfizer outside the submitted work. Dr Ong reported grants from Incyte, LEO Pharmaceuticals, Regeneron, Sanofi Genzyme; and personal fees from Incyte, Janssen, Sanofi Genzyme, AbbVie, and Pfizer outside the submitted work. Dr Lio reported personal fees for serving on advisory boards for Almirall, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science, Bristol Myers Squibb, Burt's Bees, Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant, Dermira, Exeltis, Franklin Biosciences, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, Kiniksa, KPAway, Level Ex, Lipidor, Menlo Therapeutics, Merck, Micreos Health, My-Or Diagnostics, Procter & Gamble, Realm Therapeutics, Skinfix, UCB, Unilever, Verrica; for serving on an advisory board, as a speaker, and an investigator for AbbVie and Regeneron; for serving as a consultant for Amyris; for serving as an advisor and investigator for AOBiome; for serving on an advisory board and as a speaker for Eli Lilly, Galderma, La Roche-Posay, LEO Pharmaceuticals, L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre, Sanofi; for serving as a speaker for Hyphens Pharma, Genzyme, and Incyte; grants from the Eczema Foundation and National Eczema Association (NEA) for serving as an investigator. Dr Lio also served on the board of directors for the NEA, served on the advisory board for Theraplex (with a patent pending with royalties paid), is an investor at LearnSkin, and has stock options from the following companies: Altus Health, Boston Skin Science, Concerto Biosciences, Franklin Biosciences (aka Altus labs), and Micreos Health. Dr LeBovidge reported grants from Pfizer to develop atopic dermatitis (AD) patient education materials (unrestricted educational grant) outside the submitted work. Dr Greenhawt is a member of physician and medical advisory boards for Sanofi/Regeneron, Genentech, Novartis, Pfizer, US World Meds; has received honoraria for lectures from ImSci and the MedLearningGroup; reported personal fees from DBV, Pfizer, Novartis, Aquestive, Nutricia, Sanofi/Regeneron, Genentech, Allergy Therapeutics, ALK-Abello, US World Meds, Allegenis, Prota, AstraZeneca, RMSI, and multiple state and local allergy societies; and nonfinancial support from the National Peanut Board, International Food Protein Induced Enterocolitis Syndrome Association, American College of Allergy Asthma and Immunology (ACAAI), Joint Task Force on Practice Parameters (JTFPP), Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; and grants from Agency for Healthcare Quality and Research (support ended in 2020) outside the submitted work. Mrs Capozza reported grants from LEO Pharmaceuticals, Sanofi/Regeneron, Incyte, Galderma, AbbVie, Lilly; and personal fees from Incyte and Sanofi/Regeneron outside the submitted work. Dr De Benedetto is an investigator for Dermira and Novartis; reported grants from Pfizer and Kiniksa; and personal fees from dMed Biopharmaceutical Co, Ltd (consultant) outside the submitted work. Dr Boguniewicz conducts research at Regeneron and Incyte and is part of advisory boards and consults for AbbVie, Janssen, LEO Pharmaceuticals, Lilly, Pfizer, Regeneron, Sanofi, and Genzyme outside the submitted work. Ms Smith Begolka reported grants from Pfizer paid to the institution, personal fees from Pfizer and Incyte paid to NEA, and being a salaried employee for NEA outside the submitted work. Dr Schneider reported grants from Regeneron Pharmaceuticals paid to the institution and Pfizer paid to a colleague; personal fees for serving on an advisory board from Sanofi and LEO Pharmaceuticals; and has served on the advisory board for the NEA outside the submitted work. No other disclosures were reported.
Funding/Support: This work was commissioned by the American Academy of Allergy, Asthma & Immunology (AAAAI) and ACAAI through the JTFPP to inform upcoming guidance on management of AD.
Role of the Funder/Sponsor: The funder contributed to defining the scope of the review but otherwise had no role in study design and data collection. Data were interpreted and the report drafted and submitted without funder input. The funder was provided a copy of the report at time of submission. The review team had the ability, but not obligation, to consider the funder’s feedback. The first and corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
Additional Contributions: We thank all the patients and caregiver partners part of the 2022 AAAAI/ACAAI JTFPP Atopic Dermatitis Guidelines.
Disclaimer: The authors, editors, and journal take a neutral position with respect to territorial claims in published maps and institutional affiliations.
1.Boguniewicz
M , Fonacier
L , Guttman-Yassky
E , Ong
PY , Silverberg
J , Farrar
JR . Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.
Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2. doi:
10.1016/j.anai.2017.10.039PubMedGoogle ScholarCrossref 2.Bakaa
L , Pernica
JM , Couban
RJ ,
et al. Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE.
Ann Allergy Asthma Immunol. 2022;128(6):660-668.e9. doi:
10.1016/j.anai.2022.03.024PubMedGoogle ScholarCrossref 11.Lewin
S , Bohren
M , Rashidian
A ,
et al. Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 2: how to make an overall CERQual assessment of confidence and create a Summary of Qualitative Findings table.
Implement Sci. 2018;13(suppl 1):10. doi:
10.1186/s13012-017-0689-2PubMedGoogle ScholarCrossref 12.de Wijs
LEM , van Egmond
S , Devillers
ACA , Nijsten
T , Hijnen
D , Lugtenberg
M . Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study.
Arch Dermatol Res. 2022;1-9. doi:
10.1007/s00403-021-02321-zPubMedGoogle ScholarCrossref 13.Clement
C , Ridd
MJ , Roberts
K ,
et al. Parents and GPs’ understandings and beliefs about food allergy testing in children with eczema: qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial.
BMJ Open. 2020;10(11):e041229. doi:
10.1136/bmjopen-2020-041229PubMedGoogle ScholarCrossref 14.Ameen
M , Meller
S , Pinter
A , Shear
NH , Soria
A ; (the BADEL Study Group). Perception and experience of biologic therapy in atopic dermatitis: a qualitative focus group study of physicians and patients in Europe and Canada.
Dermatol Ther (Heidelb). 2021;11(6):2159-2177. doi:
10.1007/s13555-021-00631-8PubMedGoogle ScholarCrossref 17.Boeri
M , Sutphin
J , Hauber
B , Cappelleri
JC , Romero
W , Di Bonaventura
M . Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment.
J Dermatolog Treat. 2022;33(3):1449-1458. doi:
10.1080/09546634.2020.1832185PubMedGoogle ScholarCrossref 19.Cadmus
SD , Sebastian
KR , Warren
D ,
et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study.
Pediatr Dermatol. 2019;36(4):437-441. doi:
10.1111/pde.13830PubMedGoogle ScholarCrossref 22.Djokic-Gallagher
J , Rosher
P , Oliveira
G , Walker
J . A double-blind, randomised study comparing the skin hydration and acceptability of two emollient products in atopic eczema patients with dry skin.
Dermatol Ther (Heidelb). 2017;7(3):397-406. doi:
10.1007/s13555-017-0188-zPubMedGoogle ScholarCrossref 27.Gerner
T , Haugaard
JH , Vestergaard
C ,
et al. Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia.
Pediatr Allergy Immunol. 2021;32(2):331-341. doi:
10.1111/pai.13394PubMedGoogle ScholarCrossref 28.Ghio
D , Muller
I , Greenwell
K ,
et al. ‘It’s like the bad guy in a movie who just doesn’t die:’ a qualitative exploration of young people’s adaptation to eczema and implications for self-care.
Br J Dermatol. 2020;182(1):112-118. doi:
10.1111/bjd.18046PubMedGoogle ScholarCrossref 29.Gollnick
H , Luger
T , Freytag
S , Bräutigam
M ; STABIEL study group. StabiEL: stabilization of skin condition with Elidel—a patients’ satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.
J Eur Acad Dermatol Venereol. 2008;22(11):1319-1325. doi:
10.1111/j.1468-3083.2008.02807.xPubMedGoogle ScholarCrossref 34.Howells
LM , Chalmers
JR , Cowdell
F , Ratib
S , Santer
M , Thomas
KS . ‘When it goes back to my normal I suppose’: a qualitative study using online focus groups to explore perceptions of ‘control’ among people with eczema and parents of children with eczema in the UK.
BMJ Open. 2017;7(11):e017731. doi:
10.1136/bmjopen-2017-017731PubMedGoogle ScholarCrossref 35.Howells
L , Thomas
KS , Sears
AV ,
et al; Long-term control of eczema working group for the HOME initiative. Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema.
J Eur Acad Dermatol Venereol. 2019;33(6):1124-1132. doi:
10.1111/jdv.15475PubMedGoogle ScholarCrossref 39.Jung
HJ , Bae
JY , Kim
JE ,
et al. Survey of disease awareness, treatment behavior and treatment satisfaction in patients with atopic dermatitis in Korea: a multicenter study.
J Dermatol. 2018;45(10):1172-1180. doi:
10.1111/1346-8138.14540PubMedGoogle ScholarCrossref 40.Kamei
K , Hirose
T , Yoshii
N , Tanaka
A . Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey.
J Dermatol. 2021;48(10):1491-1498. doi:
10.1111/1346-8138.16054PubMedGoogle ScholarCrossref 46.Rhun
AL , Wastiaux
HA , Moret
L ,
et al. Fears regarding the use of topical corticosteroids in atopic dermatitis: looking at the coping strategies and the role of health care providers: a qualitative study.
Educ Ther Patient/
Ther Patient Educ. 2015;7(2):20102. doi:
10.1051/tpe/2015011Google ScholarCrossref 47.Li
Y , Han
T , Li
W , Li
Y , Guo
X , Zheng
L . Awareness of and phobias about topical corticosteroids in parents of infants with eczema in Hangzhou, China.
Pediatr Dermatol. 2018;35(4):463-467. doi:
10.1111/pde.13527PubMedGoogle ScholarCrossref 49.Lundin
S , Jonsson
M , Wahlgren
CF , Johansson
E , Bergstrom
A , Kull
I . Young adults’ perceptions of living with atopic dermatitis in relation to the concept of self-management: a qualitative study.
BMJ Open. 2021;11(6):e044777. doi:
10.1136/bmjopen-2020-044777PubMedGoogle ScholarCrossref 50.Maghen
P , Unrue
EL , Oussedik
E , Cline
A , Cardwell
LA , Feldman
SR . Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis.
Br J Dermatol. 2019;181(4):842-844. doi:
10.1111/bjd.17929PubMedGoogle ScholarCrossref 51.McAlister
RO , Tofte
SJ , Doyle
JJ , Jackson
A , Hanifin
JM . Patient and physician perspectives vary on atopic dermatitis.
Cutis. 2002;69(6):461-466.
PubMedGoogle Scholar 55.Onumah
N , Kircik
L . Pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: a pilot study on patient preference.
J Drugs Dermatol. 2013;12(10):1145-1148.
PubMedGoogle Scholar 60.Roh
NK , Han
SH , Kim
MJ ,
et al. Awareness of atopic dermatitis and attitudes toward different types of medical institutions for its treatment among adult patients and the parents of pediatric patients: a survey of 500 participants.
Ann Dermatol. 2016;28(6):725-732. doi:
10.5021/ad.2016.28.6.725PubMedGoogle ScholarCrossref 63.Santer
M , Burgess
H , Yardley
L ,
et al. Managing childhood eczema: qualitative study exploring carers’ experiences of barriers and facilitators to treatment adherence.
J Adv Nurs. 2013;69(11):2493-2501. doi:
10.1111/jan.12133PubMedGoogle ScholarCrossref 66.Steinke
S , Langenbruch
A , Ständer
S , Franzke
N , Augustin
M . Therapeutic benefits in atopic dermatitis care from the patients’ perspective: results of the German national health care study ‘Atopic Health’.
Dermatology. 2014;228(4):350-359. doi:
10.1159/000358587PubMedGoogle ScholarCrossref 67.Teasdale
EJ , Muller
I , Santer
M . Carers’ views of topical corticosteroid use in childhood eczema: a qualitative study of online discussion forums.
Br J Dermatol. 2017;176(6):1500-1507. doi:
10.1111/bjd.15130PubMedGoogle ScholarCrossref 68.Thomas
C , Raibouaa
A , Wollenberg
A ,
et al. PMU105 Patient preferences for systemic atopic dermatitis treatments in the UK, France and Spain: a discrete choice experiment.
Value Health. 2020;23:S621. doi:
10.1016/j.jval.2020.08.1317Google ScholarCrossref 70.Veenje
S , Osinga
H , Antonescu
I , Bos
B , de Vries
TW . Focus group parental opinions regarding treatment with topical corticosteroids on children with atopic dermatitis.
Allergol Immunopathol (Madr). 2019;47(2):166-171. doi:
10.1016/j.aller.2018.05.007PubMedGoogle ScholarCrossref 71.Wilson
F , Harnik
E , Gore
C . 1745 Exploring parental understanding and views on topical corticosteroids (TCS) and TCS labelling in paediatric atopic dermatitis.
Allergy. 2020;75(S109):568-610.
Google Scholar 73.Zeichner
J , Feldman
S , Ervin
C , Crawford
R , Evans
E , Zielinski
M . 26652 Patient and caregiver perspectives on treatment attributes for atopic dermatitis.
J Am Acad Dermatol. 2021;85(3):AB111. doi:
10.1016/j.jaad.2021.06.461Google ScholarCrossref 74.Augustin
M , Langenbruch
A , Blome
C ,
et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation.
J Eur Acad Dermatol Venereol. 2020;34(1):142-152. doi:
10.1111/jdv.15919PubMedGoogle ScholarCrossref